2022 | Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials | Wykoff, Charles C; Abreu, Francis; Adamis, Anthony P; Basu, Karen; Eichenbaum, David A; Haskova, Zdenka; Lin, Hugh; Loewenstein, Anat; Mohan, Shaun; Pearce, Ian A; Sakamoto, Taiji; Schlottmann, Patricio G; Silverman, David; Sun, Jennifer K; Wells, John A; Willis, Jeffrey R; Tadayoni, Ramin; CHANG-HAO YANG et al. | Lancet (London, England) | 161 | | |
2024 | Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials | Wong, Tien Y; Haskova, Zdenka; Asik, Kemal; Baumal, Caroline R; Csaky, Karl G; Eter, Nicole; Ives, Jane A; Jaffe, Glenn J; Korobelnik, Jean-François; Lin, Hugh; Murata, Toshinori; Ruamviboonsuk, Paisan; Schlottmann, Patricio G; Seres, András I; Silverman, David; Sun, Xiaodong; Tang, Yannan; Wells, John A; Yoon, Young Hee; Wykoff, Charles C; CHANG-HAO YANG et al. | Ophthalmology | | | |